Oracle to buy Cerner for $28.3B
The companies struck an all-cash deal on Monday for $95-per share. Oracle plans to add a voice interface to Cerner’s electronic health record system.
Biotech Hub
Consequential convergence: The intersection of interoperability and value-based care
Interoperability has risen to the forefront, empowering providers and payers with the information they need to implement value-based care models.
Christian John Lillis, Author at MedCity News
Christian John Lillis Christian John Lillis is the Co-founder and Executive Director of the Peggy Lillis Foundation for C. diff Education & Advocacy. As head of PLF, Christian has led six national convenings of C. diff Advocates, built a 50-person volunteer Advocates Council, coordinated the first-ever C. diff Lobby Day on Capitol Hill, and produced …
Biogen slashes price of Alzheimer’s drug by half as CMS coverage decision looms
The price of Biogen Alzheimer’s disease drug Aduhelm will be cut in half at the start of 2022, a move that comes as a Medicare recommendation on coverage is expected early next year. Meanwhile, Biogen…
A conversation with the chief medical officer of AWS
A conversation with Taha Kass-Hout reveals how machine learning can be leveraged to really harness data to improve outcomes and ultimately put people on a path to precision health.
STAT+: Here are the finalists for best biopharma CEO of 2021. And a winner
.@adamfeuerstein names his best biopharma CEO of 2021, plus some runners-up.
Let’s focus on patient compliance as the problem, not adherence
The change in terminology from ‘compliance’ to ‘adherence’ is based on unfounded and untenable foundations. It conflates cause and effect, and a shift in language and mindsets can help reframe and…
Novartis, BeiGene ink another deal; plan for tests of checkpoint cancer drug combos
Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing $300 million up front, and up to $700 million more upon exercising its option on BeiGene’s antibody drug.
Biogen slashes price of Alzheimer’s drug Aduhelm in half, plans $500M in cost-cutting
Biogen said that it has reduced the price of its Alzheimer’s drug Aduhelm by half and is planning a series of cost-cutting measures across the company next year that aim to save $500 million.
Scientists are just starting to tease out the microbiome’s role in CAR-T outcomes among cancer patients
‘We are just starting to scratch the surface,” said Andrea Facciabene, a cancer immunotherapy researcher at the University of Pennsylvania.